KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Cash & Equivalents (2016 - 2025)

Merck (MRK) has disclosed Cash & Equivalents for 17 consecutive years, with $14.6 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 9.99% to $14.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.6 billion through Dec 2025, up 9.99% year-over-year, with the annual reading at $14.6 billion for FY2025, 9.99% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $14.6 billion at Merck, down from $18.2 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $18.2 billion in Q3 2025, with the low at $5.6 billion in Q1 2024.
  • Average Cash & Equivalents over 5 years is $10.0 billion, with a median of $9.2 billion recorded in 2022.
  • The sharpest move saw Cash & Equivalents plummeted 46.11% in 2023, then skyrocketed 99.72% in 2024.
  • Over 5 years, Cash & Equivalents stood at $8.1 billion in 2021, then soared by 56.79% to $12.7 billion in 2022, then tumbled by 46.11% to $6.8 billion in 2023, then skyrocketed by 93.57% to $13.2 billion in 2024, then rose by 9.99% to $14.6 billion in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $14.6 billion, $18.2 billion, and $8.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.